Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis
NCT ID: NCT05959083
Last Updated: 2025-07-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
200 participants
OBSERVATIONAL
2023-08-18
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Upadacitinib is an approved drug for treating AD. Approximately 200 adolescent and adult participants who are prescribed upadacitinib by their physician in accordance with local label will be enrolled in China.
Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed up for approximately 24 months per participant and 30 days after last treatment dose for safety data collection.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China
NCT06421740
A Study to Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real-World Setting
NCT05139836
A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
NCT05029895
A Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Chinese Participants Receiving Upadacitinib for Atopic Dermatitis (AD) Through Chart Review
NCT06503536
A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05507580
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Upadacitinib
Adolescent and adult participants will receive upadacitinib as prescribed by their physician irrespective of the study participation.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chinese adolescents (≥12 to \<18 years of age with body weight of ≥40 kg) or adults (≥18 years of age) at the time of enrollment.
* Participants eligible for initiation of Upadacitinib treatment for AD, including any required screening tests indicated per China Label.
* The decision to prescribe Upadacitinib is made prior to and independently of study participation.
Exclusion Criteria
* Currently participating in any interventional research studies.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University Third Hospital /ID# 257722
Beijing, Beijing Municipality, China
The First Affiliated Hospital Of Fujian Medical University /ID# 257725
Fuzhou, Fujian, China
Dermatology Hospital of Southern Medical University /ID# 261862
Guangzhou, Guangdong, China
The Eighth Affiliated Hospital, Sun Yat-sen universtiy /ID# 257737
Shenzhen, Guangdong, China
People's Hospital of Henan Province /ID# 257736
Zhengzhou, Henan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 257724
Wuhan, Hubei, China
The First Hospital of China Medical University /ID# 257641
Shenyang, Liaoning, China
Second Affiliated Hospital of Xian Jiaotong University /ID# 257733
Xi'an, Shaanxi, China
Shandong Dermatological Hospital /ID# 257727
Jinan, Shandong, China
Huashan Hospital, Fudan University /ID# 256456
Shanghai, Shanghai Municipality, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 257726
Shanghai, Shanghai Municipality, China
Shanghai Skin Disease Hospital /ID# 257719
Shanghai, Shanghai Municipality, China
Chengdu Second Municipal People's Hospital /ID# 257732
Chengdu, Sichuan, China
West China Hospital, Sichuan University /ID# 257720
Chengdu, Sichuan, China
Sichuan Provincial People's Hospital /ID# 263898
Chengdu, Sichuan, China
Hangzhou First People's Hospital /ID# 261867
Hangzhou, Zhejiang, China
The second affiliated hospital of Zhejiang University school of medicine /ID# 257723
Hangzhou, Zhejiang, China
Ningbo First Hospital /ID# 263884
Ningbo, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P21-702
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.